Breakthrough therapy designation to obinutuzumab for patients with lupus nephritis

The FDA recently granted breakthrough therapy designation to obinutuzumab for patients with lupus nephritis.

The designation arrived after the medication showed positive results from a phase 2 study.

Read full article ↗